Version May 2024
| Agent | Dosing frequency and timing in relation to food | Dose adjustments for baseline kidney/liver dysfunction | Major toxicities | Other |
| Imatinib | Daily (or twice daily) with food | Yes (kidney, liver) | Bone marrow suppression; fluid retention/edema; gastrointestinal effects; heart failure; hepatotoxicity. | Longest record of safety data |
| Nilotinib | Twice daily without food | Yes (liver) | Bone marrow suppression; cardiovascular events; electrolyte imbalance; hepatotoxicity. Black box warning: QT prolongation (screening required). | |
| Dasatinib | Daily with or without food | No | Bone marrow suppression; pleural/pericardial effusions; pulmonary arterial hypertension; QT prolongation; aspirin-like effect. | |
| Bosutinib | Daily with food | Yes (kidney, liver) | Bone marrow suppression; fluid retention/edema; gastrointestinal effects. | |
| Ponatinib | Daily with or without food | Yes (liver) | Bone marrow suppression; fluid retention/edema; gastrointestinal effects; heart failure; hypertension; pancreatitis; aspirin-like effect; arterial thrombosis. Black box warning: cardiovascular events; hepatic toxicity. | Active against BCR::ABL1 T315I mutation; limited long-term safety data |
| Asciminib | Daily or twice daily without food | No | Upper respiratory tract infections; musculoskeletal pain; fatigue; nausea; rash; and diarrhea. Hypertriglyceridemia; cytopenias; elevated creatine kinase; hepatotoxicity; pancreatitis. | Active against BCR::ABL1 T315I mutation; limited long-term safety data |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
